Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RHEA-1: AZD9793 in advanced or metastatic hepatocellular carcinoma
2024-516698-56-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Mar 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, open-label trial of AZD9793 in hepatocellular carcinoma (HCC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of dose-limiting toxicities, Incidence of adverse events and 3 more. Planned start Mar 2026; status: authorised.
02
Drugs
AZD9793
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2024-516698-56-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516698-56-00.